Comparison of meperidine and pancuronium for the treatment of shivering after cardiac surgery 
ratory quotient, lf the patient shivered, the measurements were recorded prior to drug treatment and repeated 30 min later following randomization to either: meperidine 0.25 mg "kg -j (Group 1), meperidine O. 5 mg 9 kg -I (Group 2) or pancuronium 0.06 mg .kg -I intravenously (Group 3). Thirty-two patients shivered and mean V Oz and ~' CO~ values were greater in the shivering group than in the nonshivering patients (V 02 334.8 --+ IZ6 vs. 240.5 +_ 8.8 ml .min-~; VC02 238.8 +-IZ2 vs 199.2 +_ 8.4 ml .rain -I, P = 0.0001). Thirty minutes following treatment the mean V'02 in Group 3 was less (215.9 +.-24.3 ml .rain -I) than in Groups I (295.9 +_ 22.0 ml .min -t) and 2 (322.7 -_+ 21.0 ml .min-J)(P < 0.01). It is concluded that drug treatment with meperidine is not as effective as pancuronium in alleviating the metabolic effects of shivering in these patients.

Les frissons aprds une chirurgie cardiaque peuvent produire des effets mEtaboliques et hEmodynamiques inddsirables. Les effets mdtaboliques des frissons et l'efficacitd du traitement avec mEp6ridine et pancuronium ont dtd ~tudi~s gt l'aide d'un
Shivering often occurs in the early recovery of patients following cardiac surgery with cardiopulmonary bypass. This shivering can be deleterious in that it has frequently been associated with adverse metabolic and haemodynamic sequelae, such as increases in heart rate, cardiac output, oxygen consumption (X/O2) and carbon dioxide production (VCO2) t and decreases in mixed venous oxygen saturation. 2 The metabolic effects of shivering can be assessed using a commercially available device (a metabolic cart) which continuously analyses expired and inspired gases, rapidly detects changes in these variables over time, and can be used to calculate ~/O2 and ~/CO2. 3 Although meperidine and pancuronium 2 have been shown to be effective in the treatment of shivering in postoperative patients, we are unaware of any study documenting the metabolic effects of shivering or its treatment using the metabolic cart in post-cardiac surgical patients.
This study was undertaken to compare the effectiveness of meperidine and pancuronium in the suppression of postoperative shivering, and to document the effects of shivering and its treatment using hemodynamic monitoring and a metabolic cart.
Methods
After obtaining institutional approval and written informed consent, 61 patients scheduled for elective coronary artery bypass surgery were enrolled in the study. Patients were maintained on their usual medications until the morning of surgery, and received remedication with morphine 10 to 15 mg and perphenazine (a phenothiazine tranquilizer) 5.0 to 7.5 mg ira, and diazepam 10 to 15 mg or lorazepam 2 to 4 mg po. Monitoring included the use of radial arterial and pulmonary artery thermodilution catheters (model 93A-131H-7F, American Edwards Laboratories), oesophageal stethoscope temperature probe and a urinary bladder temperature probe Patients were anaesthetised using fentanyl (50 to 100 I~g" kg -~) or sufentanil (15 to 30 I~g" kg -~) and diazepam (0.2 mg'kg-~). Muscle relaxation was achieved with pancuronium (0.2 mg. kg-t). Cardiopulmonary bypass (CPB) was instituted using a membrane oxygenator with intermittent cold blood cardioplegia. Following revascularization, rewarming to an oesophageal temperature of 38 ~ C occurred before termination of CPB and was maintained for at least 15 min of reperfusion time.
After surgery, patients were transferred to the Cardiovascular Intensive Care Unit (CVICU) where they underwent mechanical pulmonary ventilation with warmed and humidified inspired gases. A warming blanket was applied to all patients until the pulmonary artery temperature reached 36 ~ C.
Haemodynamic variables including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP), cardiac output (CO), cardiac index (CI) and systemic and pulmonary vascular resistances (SVR, PVR) were measured hourly.
Carbon dioxide production ('~/CO2), oxygen consumption ('~/O 2) and respiratory quotient (RQ) were obtained using a Deltatrac metabolic cart (SensorMedics Corporation, Anaheim, CA). The use of this cart has been validated in laboratory n and clinical environments S up to an FIO 2 of 0.8, 6 with a high degree of accuracy, and. good correlation with other methods of measurement. It was calibrated before use with a calibration gas comprising 96% oxygen and 4% carbon dioxide. The inspired oxygen concentration was stable and RQ was between 0.7 and 1.0 throug.hout the measurement periods. Each measurement of VO2, VCO2 and RQ comprised a mean of ten readings at one-minute intervals after stabilization. Temperatures at three sites (pulmonary artery, oesophagus, urinary bladder) were recorded every 15 min.
A shivering score was obtained every 15 min using the method proposed by Holtzclaw 7 (Table I) . If the shivering score reached 3 or 4, as graded by two independent observers (JCST, JCM), all haemodynamic, respiratory and metabolic measurements were performed. The patient was then randomized to a treatment group, There were no significant differences between groups.
the drug treatment was administered and the measurements were repeated after 30 min. Patients were randomly allocated to one of three drug treatment groups: (1) meperidine 0.25 m g . k g -~, (2) meperidine 0.5 m g . k g -I, or (3) pancuronium 0.06 m g -k g -~ iv. If, after 30 min, treatment with meperidine failed to abolish shivering (shivering score >1), the patient received pancuronium 0.06 mg. kg -t iv.
The protocol allowed patients to receive routine treatment for pain relief and sedation with morphine 2-8 mg iv as required and midazolam either by bolus or intravenous infusion of 1-3 mg. hr -I.
Data were analysed using the SAS/PC statistical package s for t tests for between-group comparisons, and repeated measures analysis of variance (RMANOVA) for multiple inter-and intra-group comparisons. A P value <0.05 was considered significant.
Results
The initial group, before randomisation, consisted of 51 men and ten women. Thirty-three of 61 of these patients shivered (54%), and this occurred three times more commonly in males (31/51) than females (2/10).
Analysis of those who shivered is based on 12 patients in Group 1, 12 patients in Group 2, and nine patients in FIGURE 1 Mean • SEM of peak oxygen consumption and carbon dioxide production in shivering and non-shivering patients (*P = 0.0001). Group 3; one patient in Group 2 was excluded due to insufficient data. Six of 12 patients in Group 1 (50%) and five of 12 in Group 2 (42%) were treatment failures who required pancuronium to stop their shivering.
Patient and surgical characteristics are summarized in Table II . The groups were matched for age, height, weight and duration of surgery. There were no differences between groups in duration of CPB, lowest temperature reached during CPB, temperature on termination of CPB or reperfusion time. Doses of anaesthetic and sedative drugs received both intra-and postoperatively were similar in the two groups.
The mean time from return to CVICU until shivering occurred was 232 --+ 81 rain and the mean temperature at which patients shivered was 35.9 ___ 0.89 ~ C.
The maximum ~/O2 values in the patients who shivered were greater than in the non-shiverers (334.8 ___ 17.6 vs 240.5 ___ 8.8 ml. min -~, P = 0.0001), as were the mean VCO 2 values (283.8 _ 17.2 vs 199.2 ___ 8.4 m l -m i n -], P = 0.0001) (Figure 1) .
In the shivering patients, there were no differences between treatment groups in ~'O2 or ~/CO2 before drug treatment or during shivering. (Figures 2 and 3 Haemodynamic variables were similar in the shivering and nonshivering patients at baseline but different for MPAP, CO, CI, and SVR at the time of shivering (see Table III ).
Discussion
Increases in VO 2 and VCO 2 occur in patients who shiver following cardiac surgery. ~' 2 These changes have been associated with increases in heart rate and mean arterial blood p r e s s u r e 9 and decreases in mixed venous oxygen saturation (SfOz).t'2 The shivering patient thus may experience increased myocardial work, with deleterious effect on the myocardial supply-demand relationship, t~ Donati et al. N showed that end tidal carbon dioxide concentrations increase in patients during rewarming after cardiac surgery, probably due to increased 'v'CO2 as a result of increases in metabolic activity. If pulmonary ventilation does not match these increases in VCO 2, hypercarbia and acidosis can result. ~2
In the current study, meperidine was administered at two different doses (0.25 mg. kg -t and 0.5 mg-kg -~) in an attempt to suppress shivering. Our success rate (50% in Group 1 and 42% in Group 2) was similar to that previously reported. ~ More importantly, although our meperidine-treated patients had clinical evidence of shivering suppression, their VO 2 and ~/CO2 values remained elevated and did not decline following treatment.
In the present study, only pancuronium was successful at suppressing the clinical and metabolic effects of shivering. Meperidine treatment of shivering, although apparently clinically effective, may delay definitive treatment of the underlying metabolic changes that occur unless facilities for ongoing monitoring of the effectiveness of treatment are available.
Numerous treatments have been proposed for the prevention and amelioration of postoperative shivering in these patients. These include heated humidification of inspired anaesthetic gases, extending rewarming of patients before discontinuation of CPB, and vasodilator therapy to allow more uniform rewarming of patients.~3-~6 None of these has been shown to be effective in minimizing the afterdrop of temperature that occurs after discontinuation of CPB or in preventing the shivering which may occur. In cardiac surgical patients, Guffin et al. were able to suppress shivering in 11 of 20 patients using meperidine 25 to 50 mg iv, with reductions in shivering and improvements of Sx;O2 .2 The remaining nine patients required pancuronium to bring about clinically acceptable values of S~702. Zwischenberger et aL have shown that patients who received neuromuscular blockers following cardiac surgery displayed smaller increases in "~/O 2 and VCO z and higher systolic blood pressure and mixed venous oxygen saturation than untreated controls, t7
We used morphine and midazolam for sedation in our patients at small doses that were similar in the shivering and non-shivering groups. Morphine suppresses shivering and its metabolic and haemodynamic sequelae following major surgery, when used in large doses (0.6 mg-kg -t over seven hours in one study), 9 but this is far in excess of the doses used in the present study (1.9 +_ 0.3 mg-hr -~ in shivering patients and 1.8 -+ 0.4 rag. hr -1 in non-shivering patients) (Table II) . Others have not found morphine to be as successful as other agents in suppressing shivering in general surgical ~8 or cardiac surgical patients . 2 The haemodynamic changes found in the present study in the shivering patients (increases in CO, CI, SVR, and MPAP) are in keeping with those shown in previous studies t'2'15 and reflect the increases in myocardial work that occur in these patients.
We conclude that shivering following cardiac surgery is most effectively treated with pancuronium, and the effects of treatment are best followed using continous monitoring of metabolic variables using a metabolic cart.
